TY - JOUR
T1 - Hyper-activated IRF-1 and STAT1 contribute to enhanced interferon stimulated gene (ISG) expression by interferon alpha and gamma co-treatment in human hepatoma cells
AU - Zhang, Xiao-Nan
AU - Liu, Jiang-Xia
AU - Hu, Yun-Wen
AU - Chen, Hui
AU - Yuan, Zheng-Hong
PY - 2006/9/22
Y1 - 2006/9/22
N2 - Previous reports suggest that type I and type II Interferon can co-operatively inhibit some virus replication, e.g. HCV, SARS-CoV, HSV-1. To find out the molecular mechanism underlying this phenomenon, we analyzed the transcription profile stimulated by IFN-alpha and IFN-gamma in Huh-7 cells and found that the transcription of a subset of IFN stimulated genes (ISGs) including BclG, XAF1, TRAIL and TAP1 was enhanced when IFN-alpha and gamma were both present. Promoter analysis of BclG revealed that IRF-1 and STAT1 were both required in this process. Enhanced IRF-1/DNA complex formation was observed in interferon co-treatment group by gel shift analysis. Furthermore, IRF-1 activation was found to be generally required in this cluster of ISGs. STAT1 tyrosine phosphorylation was elevated by IFN combination treatment, however, only the hyper-transactivation of GAS but not ISRE was observed. In conclusion, hyper-activation of IRF-1 and elevated STAT1 dimer formation may be two general switches which contribute to a much more robust antiviral symphony against virus replication when type I and type II IFNs are co-administered.
AB - Previous reports suggest that type I and type II Interferon can co-operatively inhibit some virus replication, e.g. HCV, SARS-CoV, HSV-1. To find out the molecular mechanism underlying this phenomenon, we analyzed the transcription profile stimulated by IFN-alpha and IFN-gamma in Huh-7 cells and found that the transcription of a subset of IFN stimulated genes (ISGs) including BclG, XAF1, TRAIL and TAP1 was enhanced when IFN-alpha and gamma were both present. Promoter analysis of BclG revealed that IRF-1 and STAT1 were both required in this process. Enhanced IRF-1/DNA complex formation was observed in interferon co-treatment group by gel shift analysis. Furthermore, IRF-1 activation was found to be generally required in this cluster of ISGs. STAT1 tyrosine phosphorylation was elevated by IFN combination treatment, however, only the hyper-transactivation of GAS but not ISRE was observed. In conclusion, hyper-activation of IRF-1 and elevated STAT1 dimer formation may be two general switches which contribute to a much more robust antiviral symphony against virus replication when type I and type II IFNs are co-administered.
KW - Base Sequence
KW - Carcinoma, Hepatocellular/genetics
KW - Cell Line, Tumor
KW - Dimerization
KW - Gene Expression/drug effects
KW - Humans
KW - Interferon Regulatory Factor-1/antagonists & inhibitors
KW - Interferon Type I/pharmacology
KW - Interferon-gamma/pharmacology
KW - Liver Neoplasms/genetics
KW - Phosphorylation
KW - Promoter Regions, Genetic
KW - Proto-Oncogene Proteins c-bcl-2/genetics
KW - RNA, Small Interfering/genetics
KW - Recombinant Proteins
KW - STAT1 Transcription Factor/chemistry
KW - Transfection
U2 - 10.1016/j.bbaexp.2006.08.003
DO - 10.1016/j.bbaexp.2006.08.003
M3 - Article
C2 - 16987558
SN - 0006-3002
VL - 1759
SP - 417
EP - 425
JO - Biochimica et Biophysica Acta: international journal of biochemistry and biophysics
JF - Biochimica et Biophysica Acta: international journal of biochemistry and biophysics
IS - 8-9
ER -